April 7, 2020
InGeneron Announces Publication of Favourable Results for its Rotator Cuff Feasibility Study in the Journal of Orthopaedic Surgery and Research
Houston, TX, USA – FDA-approved randomized controlled feasibility study finds InGeneron’s regenerative cell therapy to significantly reduce pain and improve shoulder function over corticosteroid injection to address symptomatic partial-thickness rotator cuff tears.
October 31, 2019
InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure
Houston, TX, USA – Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.
June 11, 2019
InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic
Houston, TX, USA – Company raises up to an additional $23 million from strategic partner Sanford Health to advance a pivotal program in rotator cuff tendinopathy.
May 15, 2019
Houston, TX, USA – Company enrolls first patients in multi-center trial evaluating regenerative cell therapy at the point of care for partial rotator cuff tears.
March 21, 2019
InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration
Houston, TX, USA – Autologous point-of-care regenerative cell therapy shows favourable safety profile and promising histological outcome in a clinical case study of guided bone regeneration.
January 23, 2019
Houston, TX, USA – Company enrolls first patients in feasibility studies for chronic back pain and wrist osteoarthritis, setting clinical development focus on orthopaedic indications.
December 12, 2018
InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy
Houston, TX, USA – Feasibility study meets primary endpoints and paves the way for a pivotal study in 2019.
October 4, 2017
Houston, TX, USA and Munich, Germany – InGeneron announced today that Angelo Moesslang, PhD, former Chief Financial Officer (CFO) of Fresenius Medical Care North America, has joined InGeneron and will serve as the new Chief Executive Officer (CEO).
September 18, 2017
InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology
Houston, TX, USA and Munich, Germany – Point-of-care regenerative cell therapy demonstrates promising safety and tolerability profile and closure of venous chronic leg wounds as conducted by Technical University Munich.
March 6, 2017
Houston, Texas, and Sioux Falls, South Dakota – In addition to clinical trial cooperation with one of the largest U.S. hospital groups, the investment will support clinical development in orthopaedics and wound healing.
February 14, 2017
Houston, TX, USA – InGeneron, Inc. today announced changes in its leadership team. Michael Coleman, PhD, has stepped down as President and CEO and will join InGeneron’s Scientific Advisory Board. Ron Stubbers, MBA, formerly InGeneron’s Vice President of Operations, has been appointed President. The company also announced the appointment of Glenn Winnier, PhD, as Chief Scientific Officer.
December 5, 2016
InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences
Cambridge, MA, USA and Berlin, Germany – InGeneron, a regenerative medicine and biotechnology company, today announced its acceptance to the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi).
November 21, 2016
InGeneron Announces Presentation of Results from Investigator-Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS
Houston, TX, USA and Munich, Germany – InGeneron, Inc. today announced the presentation of initial data from an investigator-initiated case series using its proprietary adipose-derived regenerative cell (ADRC) technology for the treatment of facet joint syndrome, one of the major causes of chronic back pain.